Exposure to the disease and lack of enough critical medical devices are the biggest challenges facing healthcare professionals during the coronavirus pandemic, found a Verdict poll.

The poll, which was run from 26 March to 01 April, tried to identify the biggest challenge among six of the most common challenges healthcare service providers face during the pandemic.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The challenges include disease exposure, lack of critical medical devices, shortage of healthcare professionals, dwindling stock of medical supplies, financial burden on hospital, and insufficient hospital beds.

More than 50% of the respondents found the first two among the above to be the most challenging, with disease exposure being the most challenging, as polled by 26% of the respondents. Shortage of professionals and diminishing stock of medical supplies are the next bigger challenges, as polled by 16% each.

Coronavirus healthcare challenges

Financial burden on hospital and insufficient hospital beds are lesser challenges, as opined by 8% and 7% of the respondents, respectively.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The analysis is based on 722 responses received during the poll period.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact